X4 Pharmaceuticals, Inc.
XFOR
$4.10
$0.030.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.11M | 33.98M | 32.77M | 31.36M | 2.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.11M | 33.98M | 32.77M | 31.36M | 2.56M |
| Cost of Revenue | 5.76M | 5.70M | 5.57M | 5.51M | 797.00K |
| Gross Profit | 29.36M | 28.28M | 27.20M | 25.85M | 1.76M |
| SG&A Expenses | 40.12M | 47.88M | 55.35M | 59.10M | 61.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.30M | 127.98M | 138.66M | 144.92M | 143.96M |
| Operating Income | -82.18M | -94.00M | -105.89M | -113.56M | -141.40M |
| Income Before Tax | -79.16M | -94.80M | -101.63M | 14.92M | -37.14M |
| Income Tax Expenses | 41.00K | 299.00K | 344.00K | 325.00K | 310.00K |
| Earnings from Continuing Operations | -79.20 | -95.10 | -101.98 | 14.60 | -37.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.20M | -95.10M | -101.98M | 14.60M | -37.45M |
| EBIT | -82.18M | -94.00M | -105.89M | -113.56M | -141.40M |
| EBITDA | -80.91M | -92.67M | -104.52M | -112.35M | -140.61M |
| EPS Basic | -4.34 | -10.01 | -14.80 | 2.27 | -5.54 |
| Normalized Basic EPS | -2.63 | -6.15 | -9.22 | -8.37 | -13.25 |
| EPS Diluted | -4.34 | -10.01 | -14.80 | 2.24 | -5.57 |
| Normalized Diluted EPS | -2.64 | -6.15 | -9.22 | -8.37 | -13.25 |
| Average Basic Shares Outstanding | 168.08M | 64.29M | 27.71M | 26.98M | 26.81M |
| Average Diluted Shares Outstanding | 168.11M | 64.32M | 27.74M | 27.02M | 26.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |